Pinpoint Science

Executive Summary

Pinpoint Science is a San Diego-based diagnostics company developing a next-generation silicon chip nanopore platform aimed at delivering high sensitivity and specificity for detection applications. Founded in 2015, the company leverages scalable nanosensor technology to transform diagnostic testing, potentially enabling rapid, accurate, and low-cost detection of pathogens, biomarkers, or other analytes. By utilizing a solid-state nanopore approach, Pinpoint Science seeks to overcome limitations of traditional diagnostic methods, such as PCR or immunoassays, offering a versatile platform that could be deployed in point-of-care settings. The company operates in the competitive diagnostics space, where innovation in biosensing is critical for addressing unmet needs in infectious disease, oncology, and personalized medicine. While still in a development stage, Pinpoint Science's technology holds promise for significant impact if successfully commercialized. Although Pinpoint Science has not publicly disclosed funding rounds or revenue, its proprietary nanotechnology positions it as a potential disruptor in the diagnostics market. Key challenges include scaling manufacturing, demonstrating clinical utility, and navigating regulatory pathways. The company's progress will depend on strategic partnerships and securing capital to advance its platform. With the global diagnostics market expanding, Pinpoint Science's ability to achieve key milestones—such as prototype validation or clinical collaborations—will be critical for its growth trajectory. The conviction score reflects the technology's promise tempered by the early stage and competitive landscape.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Funding Round Closure70% success
• Q4 2026Initial Prototype Validation or Proof-of-Concept Data Release60% success
• Q1 2027Strategic Partnership with Diagnostics or Pharma Company50% success